| Cover | Jan. 23, 2023 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | This Form 8-K/A amends Item 1.01 and 9.01 of the Current Report on Form 8-K, originally filed on January 23, 2023 (the “Original 8-K”) of Iovance Biotherapeutics, Inc. (the “Company”). The Original 8-K reported (x) the entry of the Company and its newly formed, wholly owned subsidiary, Iovance Biotherapeutics UK Ltd (“Purchaser”) into an Option Agreement (the “Agreement”) with Clinigen Holdings Limited, Clinigen Healthcare Limited, and Clinigen, Inc. and (y) that the Company has agreed to non-binding terms related to a proposed secured line of credit of up to $100.0 million from Quogue Capital LLC (the “Line of Credit”). This Current Report on Form 8-K/A amends the Original 8-K to file as an exhibit the Agreement as described in the Original 8-K. Following the Company’s entry into a binding, definitive agreement regarding the Line of Credit, the Company will file a copy of such agreement by amendment to the Original 8-K on Form 8-K/A or as an exhibit with the next periodic report. Except as expressly stated herein and below, this Form 8-K/A does not amend or update any other information in the Original 8-K. |
| Document Period End Date | Jan. 23, 2023 |
| Entity File Number | 001-36860 |
| Entity Registrant Name | IOVANCE BIOTHERAPEUTICS, INC. |
| Entity Central Index Key | 0001425205 |
| Entity Tax Identification Number | 75-3254381 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 825 Industrial Road |
| Entity Address, Address Line Two | Suite 400 |
| Entity Address, City or Town | San Carlos |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94070 |
| City Area Code | 650 |
| Local Phone Number | 260-7120 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common stock, par value $0.000041666 per value |
| Trading Symbol | IOVA |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
